Olivier Bergis

1.4k total citations
19 papers, 788 citations indexed

About

Olivier Bergis is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, Olivier Bergis has authored 19 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Cellular and Molecular Neuroscience and 2 papers in Surgery. Recurrent topics in Olivier Bergis's work include Receptor Mechanisms and Signaling (9 papers), Neuroscience and Neuropharmacology Research (8 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Olivier Bergis is often cited by papers focused on Receptor Mechanisms and Signaling (9 papers), Neuroscience and Neuropharmacology Research (8 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Olivier Bergis collaborates with scholars based in France, United States and Réunion. Olivier Bergis's co-authors include Guy Griebel, Patrick Avenet, Jeanne Stemmelin, Philippe Pichat, Denis Boulay, B. Scatton, Jean-Paul Terranova, Caroline Cohen, Vincent Santucci and Susan J. Sara and has published in prestigious journals such as Journal of Biological Chemistry, Scientific Reports and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Olivier Bergis

19 papers receiving 769 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olivier Bergis France 14 432 408 185 137 78 19 788
Philippe Pichat France 16 424 1.0× 448 1.1× 206 1.1× 125 0.9× 100 1.3× 26 981
S.N. Mitchell United Kingdom 15 610 1.4× 512 1.3× 161 0.9× 179 1.3× 75 1.0× 19 949
Valérie Pasteau France 11 495 1.1× 459 1.1× 123 0.7× 107 0.8× 74 0.9× 12 918
Ruggero Galici United States 16 700 1.6× 488 1.2× 121 0.7× 234 1.7× 86 1.1× 24 1.1k
Karla Drescher Germany 17 607 1.4× 488 1.2× 166 0.9× 149 1.1× 54 0.7× 31 1.0k
T. Nabeshima Japan 15 548 1.3× 388 1.0× 138 0.7× 156 1.1× 71 0.9× 42 890
Mahomi Kuroiwa Japan 17 530 1.2× 588 1.4× 206 1.1× 103 0.8× 43 0.6× 27 985
M.B. Hesselink Netherlands 18 665 1.5× 403 1.0× 118 0.6× 128 0.9× 82 1.1× 30 955
Mike Bickerdike United Kingdom 10 492 1.1× 283 0.7× 109 0.6× 71 0.5× 62 0.8× 15 741
Mark D. Black United States 17 595 1.4× 437 1.1× 112 0.6× 110 0.8× 50 0.6× 28 958

Countries citing papers authored by Olivier Bergis

Since Specialization
Citations

This map shows the geographic impact of Olivier Bergis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Bergis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Bergis more than expected).

Fields of papers citing papers by Olivier Bergis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Bergis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Bergis. The network helps show where Olivier Bergis may publish in the future.

Co-authorship network of co-authors of Olivier Bergis

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Bergis. A scholar is included among the top collaborators of Olivier Bergis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Bergis. Olivier Bergis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chemello, Kévin, Sandra Beeské, Thi Thu Trang Tran, et al.. (2020). Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab. JACC Basic to Translational Science. 5(6). 549–557. 19 indexed citations
2.
Griebel, Guy, Jeanne Stemmelin, Mati Lopez‐Grancha, et al.. (2018). The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Scientific Reports. 8(1). 2416–2416. 63 indexed citations
3.
Griebel, Guy, Philippe Pichat, Denis Boulay, et al.. (2016). The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports. 6(1). 35320–35320. 40 indexed citations
4.
Boulay, Denis, et al.. (2013). Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats. Behavioural Pharmacology. 24(7). 543–551. 22 indexed citations
5.
Potestio, Lisa, Philippe Pichat, Olivier Bergis, et al.. (2010). The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. Pharmacology Biochemistry and Behavior. 98(3). 405–411. 6 indexed citations
6.
Boulay, Denis, Olivier Bergis, Patrick Avenet, & Guy Griebel. (2009). The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice. Neuropsychopharmacology. 35(2). 416–427. 37 indexed citations
7.
Stemmelin, Jeanne, Caroline Cohen, Jean-Paul Terranova, et al.. (2007). Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders. Neuropsychopharmacology. 33(3). 574–587. 90 indexed citations
8.
Louis, Caroline, Jeanne Stemmelin, Denis Boulay, et al.. (2007). Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacology Biochemistry and Behavior. 89(1). 36–45. 43 indexed citations
9.
Boulay, Denis, Philippe Pichat, Olivier Bergis, Patrick Avenet, & Guy Griebel. (2007). P.3.d.009 Effects of SSR103800, a novel GlyT1 inhibitor, on the behavior of NMDA Nr1 hypomorphic mice, a model of schizophrenia. European Neuropsychopharmacology. 17. S478–S479. 2 indexed citations
10.
Pichat, Philippe, Olivier Bergis, Jean-Paul Terranova, et al.. (2006). SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia. Neuropsychopharmacology. 32(1). 17–34. 207 indexed citations
11.
Urani, Alexandre, Olivier Bergis, & Guy Griebel. (2006). P.5.f.001 SSR180711, an α7 nicotinic receptor partial agonist, reverses memory deficits induced by β25-35 amyloid peptide icv administration in mice. European Neuropsychopharmacology. 16. S489–S489. 1 indexed citations
12.
Stemmelin, Jeanne, Caroline Cohen, Olivier Bergis, & Guy Griebel. (2005). A76A THE ??7nACh RECEPTOR AGONIST, SSR180711, DISPLAYS ANTIDEPRESSANT-LIKE EFFECTS IN RODENTS. Behavioural Pharmacology. 16(Supplement 1). S47–S47. 1 indexed citations
13.
Depoortère, Ronan, Denis Boulay, Ghislaine Perrault, et al.. (2003). SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity. Neuropsychopharmacology. 28(11). 1889–1902. 48 indexed citations
14.
Moser, Paul, Olivier Bergis, Samir Jegham, et al.. (2002). SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties. Journal of Pharmacology and Experimental Therapeutics. 302(2). 731–741. 86 indexed citations
15.
Ruano, Diego, Francisco Araujo, Elisa Revilla, et al.. (2000). GABAA and α-Amino-3-hydroxy-5-methylsoxazole-4-propionate Receptors Are Differentially Affected by Aging in the Rat Hippocampus. Journal of Biological Chemistry. 275(26). 19585–19593. 32 indexed citations
16.
Curet, O., Patrick Avenet, H. Depoortere, et al.. (1998). Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. Journal of Affective Disorders. 51(3). 287–303. 23 indexed citations
17.
Caille, D., et al.. (1996). Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 265–277. 36 indexed citations
18.
Caille, D., et al.. (1992). PHARMACOLOGICAL PROFILE OF BEFLOXATONE, A NEW REVERSIBLE MAO-A INHIBITOR. Clinical Neuropharmacology. 15. 423B–423B. 2 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philippe Pichat Breakdown of academic impact, for papers by S.N. Mitchell Breakdown of academic impact, for papers by Valérie Pasteau Breakdown of academic impact, for papers by Ruggero Galici Breakdown of academic impact, for papers by Karla Drescher Breakdown of academic impact, for papers by T. Nabeshima Breakdown of academic impact, for papers by Mahomi Kuroiwa Breakdown of academic impact, for papers by M.B. Hesselink Breakdown of academic impact, for papers by Mike Bickerdike Breakdown of academic impact, for papers by Mark D. Black
Rankless by CCL
2026